New York, United States
Evvy, founded in 2020 and headquartered in the United States, is innovating in the realm of women's health through its pioneering work with the vaginal microbiome. Their slogan, "Precision women's healthcare, powered by the vaginal microbiome," underscores their commitment to revolutionizing the field.
The company distinguishes itself by unlocking precision healthcare via overlooked female biomarkers. This approach has attracted investment from eminent investors like General Catalyst, Left Lane Capital, and LabCorp. The experienced team, comprising top OB/GYNs and microbiome researchers from prestigious institutions such as UCSF and Harvard, adds significant credibility.
Evvy's Vaginal Health Test is notable as the first at-home test using metagenomic sequencing for the vaginal microbiome, leading the way in home-based, precision healthcare. Recently, they secured a $14M Series A investment led by Left Lane Capital, affirming confidence in their growth trajectory. With their comprehensive platform, Evvy is poised to reshape the landscape of women's healthcare by building datasets that deepen the understanding of complex female health issues.
